 |
|
The Epidemiology of Major Depressive Disorder
Results From the National Comorbidity Survey Replication (NCS-R)
Ronald C. Kessler, PhD;
Patricia Berglund, MBA;
Olga Demler, MS;
Robert Jin, MA;
Doreen Koretz, PhD;
Kathleen R. Merikangas, PhD;
A. John Rush, MD;
Ellen E. Walters, MS;
Philip S. Wang, MD, DrPH
JAMA. 2003;289:3095-3105.
ABSTRACT
| |
Context Uncertainties exist about prevalence and correlates of major depressive disorder (MDD).
Objective To present nationally representative data on prevalence and correlates of MDD by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, and on study patterns and correlates of treatment and treatment adequacy from the recently completed National Comorbidity Survey Replication (NCS-R).
Design Face-to-face household survey conducted from February 2001 to December 2002.
Setting The 48 contiguous United States.
Participants Household residents ages 18 years or older (N = 9090) who responded to the NCS-R survey.
Main Outcome Measures Prevalence and correlates of MDD using the World Health Organization's (WHO) Composite International Diagnostic Interview (CIDI), 12-month severity with the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), the Sheehan Disability Scale (SDS), and the WHO disability assessment scale (WHO-DAS). Clinical reinterviews used the Structured Clinical Interview for DSM-IV.
Results The prevalence of CIDI MDD for lifetime was 16.2% (95% confidence interval [CI], 15.1-17.3) (32.6-35.1 million US adults) and for 12-month was 6.6% (95% CI, 5.9-7.3) (13.1-14.2 million US adults). Virtually all CIDI 12-month cases were independently classified as clinically significant using the QIDS-SR, with 10.4% mild, 38.6% moderate, 38.0% severe, and 12.9% very severe. Mean episode duration was 16 weeks (95% CI, 15.1-17.3). Role impairment as measured by SDS was substantial as indicated by 59.3% of 12-month cases with severe or very severe role impairment. Most lifetime (72.1%) and 12-month (78.5%) cases had comorbid CIDI/DSM-IV disorders, with MDD only rarely primary. Although 51.6% (95% CI, 46.1-57.2) of 12-month cases received health care treatment for MDD, treatment was adequate in only 41.9% (95% CI, 35.9-47.9) of these cases, resulting in 21.7% (95% CI, 18.1-25.2) of 12-month MDD being adequately treated. Sociodemographic correlates of treatment were far less numerous than those of prevalence.
Conclusions Major depressive disorder is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment. While the recent increase in treatment is encouraging, inadequate treatment is a serious concern. Emphasis on screening and expansion of treatment needs to be accompanied by a parallel emphasis on treatment quality improvement.
INTRODUCTION
Although community surveys of mental disorders have been conducted in the United States since the end of World War II,1-3 it was not until the early 1980s that fully structured lay interviews were developed to diagnose specific mental disorders. The first such instrument was the Diagnostic Interview Schedule (DIS),4 which was developed for use in the Epidemiologic Catchment Area (ECA) study5 to estimate the general population prevalence of mental disorders by Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III) criteria.6 Major depressive disorder (MDD) prevalence estimates in the ECA sites were 3.0% to 5.9% for lifetime and 1.7% to 3.4% for 12-month.7
The first nationally representative survey using a method similar to the ECA, the National Comorbidity Survey (NCS),8 was conducted a decade later in 1990-1992. The NCS diagnostic instrument was a modified version of the Composite International Diagnostic Interview (CIDI)9 to assess mental disorders by Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R) criteria.10 The NCS age range was 15 years to 54 years, rather than 18 years or older in the ECA. The prevalence estimates of MDD in the NCS were substantially higher than in the ECA: 14.9% for lifetime and 8.6% for 12-month.11
Despite their different prevalence estimates, the ECA and NCS results were very similar in finding early age of onset of MDD12-13 and high comorbidity with other DSM disorders.11, 14 A methodological study showed that the ECA-NCS prevalence differences in the age range of 18 years to 54 years could be substantially reduced by combining the 2 waves of ECA data to make up for the memory priming strategies and respondent motivation techniques used in the NCS.15
Although the estimated number of individuals in the total population who seek treatment for a mental health problem in a given year was somewhat lower in the ECA (12.3%) than the NCS (13.3%), 12-month treatment among respondents who met criteria for MDD was higher in the ECA (53.9%) than in the NCS (36.4%).16-17 A plausible interpretation is that the higher NCS prevalence estimate included more mild cases, with patients with mild MDD less likely to seek treatment. Consistent with this possibility, multiplication of estimated prevalence by conditional treatment rate leads to an estimate that 2.7% of the population was in treatment for MDD in the 12 months before the ECA survey compared with 3.1% before the NCS survey.
In the decade since the NCS was conducted, a large increase in the proportion of Americans who receive medication for depression was reported18 and a number of large programs to promote awareness of depression were launched.19-20 At least part of this growth in depression awareness and treatment has occurred as a result of a growing realization that depression is a very common and very serious illness.21-22 Indeed, the World Health Organization (WHO) now ranks major depression as one of the most burdensome diseases in the world.23
This growing recognition of the public health burden of depression also has led to the development and evaluation of model primary care programs for depression detection and treatment.24-26 Even though a number of these programs have been shown to be cost-effective, dissemination has been hampered by reluctance to implement them on the part of primary care physicians.27
During this same time period, the American Psychiatric Association introduced the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) system, which emphasizes the clinical significance requirement for a diagnosis of MDD more prominently than did in the earlier DSM editions.28 This new emphasis occurred, in no small part, in reaction to the perception that the prevalence estimates in the ECA study were unrealistically high. The even higher NCS estimates, which were published only after the DSM-IV criteria were established, only reinforced this concern.15 Indeed, a recent critique of the ECA and NCS argued that a substantial proportion of respondents classified as cases were clinically insignificant, leading to an overestimation of the 12-month depression prevalence of 29% in the ECA and of 58% in the NCS.29 However, this critique was based on the use of imprecise indicators for severity symptoms, raising questions about adjusted prevalence estimates.30
Based on the introduction of the DSM-IV criteria, in conjunction with evidence of changes in treatment over the past decade, a new national survey of mental disorders was conducted in 2001-2002. The survey was designed to update information on the prevalence, correlates, and clinical significance of DSM disorders, and to study patterns and correlates of treatment and treatment adequacy. The current report is the first presentation of results from this new survey, the National Comorbidity Survey Replication (NCS-R).31
METHODS
Participants
The NCS-R is a nationally representative face-to-face household survey of 9090 respondents ages 18 years or older conducted between February 2001 and December 2002. Respondents were selected from a multistage area probability sample of the noninstitutionalized civilian population in the 48 contiguous states. The response rate was 73.0%. All respondents were administered a part 1 diagnostic interview as described below, while 5554 respondents also received a part 2 interview that included assessments of risk factors and additional mental disorders. The sample receiving part 2 consisted of all respondents who screened positive for any disorder found in part 1 plus a probability subsample of other part 1 respondents.
The sample receiving part 1 was weighted to adjust for differential probabilities of selection within households and for differences in intensity of recruitment effort among hard-to-recruit cases and poststratified to match the 2000 census population distribution on a number of geographic and sociodemographic variables. The sample receiving part 2 was additionally weighted to adjust for differential probabilities of selection. The weighted sample distributions closely match those of the US population on a variety of sociodemographic and geographic variables (Table 1).
|
|
|
|
Table 1. Sociodemographic Distribution of the National Comorbidity Survey Replication (NCS-R) Sample Compared With the US Population
|
|
|
A probability sample of 308 NCS-R respondents completed a clinical reappraisal interview to evaluate lifetime diagnoses, and a nonoverlapping probability sample of 335 respondents completed a separate reappraisal interview to evaluate 12-month diagnoses. These reappraisal samples oversampled CIDI cases. The data were weighted to adjust for this oversampling so that estimates of sensitivity, specificity, and total classification accuracy would be unbiased.
Recruitment to the initial NCS-R interview began with a letter and study fact brochure mailed to sample households followed by an in-person interviewer visit. Interviewers explained the study procedures and obtained verbal informed consent before beginning the interview. Participants received $50 as a gift to thank them for participating. Recruitment and consent procedures were approved by the human subjects committees of both Harvard Medical School and the University of Michigan.
Measures
Diagnostic Assessment. The NCS-R diagnostic instrument was an expanded version of the WHO's CIDI,9 a fully structured instrument for use by trained interviewers who do not have clinical experience. Diagnoses are based on DSM-IV criteria.28 Organic exclusions and diagnostic hierarchy rules were both applied in making diagnoses. In addition to the prevalence and correlates of MDD, in this article we also report comorbidity with anxiety disorders (panic disorder, agoraphobia without panic, social anxiety disorder, specific phobia, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), substance use disorders (alcohol and drug abuse and dependence), and a group of disorders that we refer to as "impulse-control disorders" (intermittent explosive disorder, antisocial personality disorder, bulimia, and pathological gambling).
Previous methodological research documented acceptable-to-good concordance between the NCS/CIDI diagnoses and blind clinical diagnoses, but found that the NCS CIDI overdiagnosed MDD because of false-positive assessments of dysphoria and anhedonia.32 The CIDI false-positive assessments included both respondents with clinically nonsignificant distress and those whose symptoms did not persist for most of the day, nearly every day, or for 2 weeks or longer. The NCS-R revisions attempted to correct these problems by including explicit probes for severity of dysphoria and anhedonia, by requiring clinically significant distress or impairment associated with these symptoms, and by asking separate questions about symptom duration (hours per day, days per week, and duration of depressive episodes).
The core of the clinical reappraisal interviews was the structured clinical interview for DSM-IV (SCID),33 a diagnostic interview that requires clinical expertise to administer. Nonaffective psychosis and mania were not included in the SCID because they are being assessed in separate, in-progress, focused reappraisal studies. Because of the absence of mania, the SCID cannot be used to generate diagnoses of MDD. However, it can be used to diagnose major depressive episode (MDE). A comparison of the CIDI and SCID for MDE classifications in the clinical reappraisal samples (Table 2) shows good concordance for lifetime ( = .59; 95% CI, .47-.71) and fair concordance for 12-month ( = .40; 95% CI, .20-.60) estimates. CIDI lifetime prevalence for MDE is significantly lower than SCID prevalence ( 21 = 8.1, P = .004) while CIDI 12-month prevalence is marginally higher than SCID prevalence (21 = 3.2, P = .07).
|
|
|
|
Table 2. Correspondence Between Diagnoses of DSM-IV Major Depressive Episode in the Weighted Part 1 NCS-R (CIDI) Sample and the Weighted Clinical Reinterview Samples (SCID)
|
|
|
Role Impairment. Respondents with CIDI/DSM-IV 12-month MDD were administered the Sheehan Disability Scale (SDS)34 to assess the extent to which depression interfered with functioning in work, household, relationship, and social roles in the worst month of the past year. Responses were scored with a 0-to-10 visual analogue scale having response options labeled none (0), mild (1-3), moderate (4-6), severe (7-9), and very severe (10). In addition, an open-ended question asked respondents to estimate the number of days in the past 365 days when they were "totally unable to work or carry out your normal activities" because of depression.
All respondents to part 2 of the NCS-R completed the WHO disability assessment schedule (WHO-DAS)35 to assess functional impairments in 6 domains during the past 30 days: domain 1, the number of days in the past 30 days when the respondent was completely unable to work or carry out their normal activities because of physical or mental health problems; and domains 2 to 6, the severity-persistence of impairments in 5 domains of functioning during the same time period. These domains include self-care (eg, bathing, dressing), mobility (eg, standing, walking), cognition (eg, concentrating, remembering), social functioning (eg, conversing, maintaining emotional control while around others), and role functioning (eg, quality and quantity of normal activities at home or work). All 6 WHO-DAS scales were transformed to a theoretical range of 0 (no impairment at any time in the past 30 days) to 1.0 (complete inability to perform the functions throughout the full 30 days).
Symptom Severity. Respondents who met CIDI/DSM-IV criteria for 12-month MDD were self-administered a truncated version of the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR)36 to assess symptom severity in the worst month of the past year. The QIDS-SR is a fully structured measure that is strongly related both to the clinician-administered Inventory of Depressive Symptomology (IDS-C)37 and to the Hamilton Rating Scale of Depression (HRSD).38 Transformation rules developed for the QIDS-SR39 were used to convert scores into clinical severity categories mapped to conventional HRSD ranges of none (ie, not clinically depressed), mild, moderate, severe, and very severe.
12-Month Treatment. All respondents to part 2 of the NCS-R were asked about receiving 12-month treatment for emotional problems, the type of professional seen, as well as use of support groups, self-help groups, and hotlines. Number and duration of 12-month visits also were assessed. Responses were used to classify 12-month treatment in the specialty mental health (SMH) sector (inpatient treatment or outpatient treatment with a psychiatrist, psychologist, any other mental health professional, or a social worker or counselor in a mental health specialty setting, or use of a hotline), the general medical (GM) sector (outpatient treatment with a primary care physician, other medical specialist, nurse, or any other health professional not previously mentioned), the human services (HS) sector (outpatient treatment with a religious or spiritual advisor or with a social worker or counselor in any setting other than a specialty mental health setting), and the complementary-alternative medical (CAM) sector (outpatient treatment with any other type of healer, participation in an internet support group, or participation in a self-help group). In addition, a pharmaco-epidemiologic section asked respondents about use of psychotropic medications in the past 12 months. Information was recorded by having respondents give their medicine bottles to the interviewer to inspect and to record the type of medication, duration of treatment, maximum prescribed dose, and specialty of prescribing physician.
Based on the above data, minimally adequate medical treatment for MDD was defined as receiving either (1) at least 4 outpatient visits with any type of physician for pharmacotherapy that included use of either an antidepressant or mood stabilizer for a minimum of 30 days or (2) at least 8 outpatient visits with any professional in the specialty mental health sector for psychotherapy lasting a mean of at least 30 minutes. The decision to require at least 4 pharmacotherapy visits was based on the recommendation from evidence-based treatment guidelines that no fewer than 4 visits for follow-up and medication monitoring were required during the acute and continuation phases of treatment for depression.40-41 At least 8 psychotherapy visits were required based on evidence from clinical trials that time-limited depression psychotherapy treatment with demonstrated effectiveness requires at least 8 sessions.40-41
Human services and CAM treatments were classified as not being adequate based on the absence of experimental data documenting effectiveness in treating MDD. Health care treatment, which was defined as treatment in either the SMH or GM sectors, was considered inadequate when this treatment failed to meet either of the above 2 criteria for minimally adequate treatment. Respondents who reported 12-month use of psychotropic medications under the supervision of a health care professional, but who never made a visit to that professional at any time during those 12 months, were coded as receiving inadequate health care treatment, but not receiving either inadequate SMH or inadequate GM treatment.
Sociodemographics. A standard battery of sociodemographic variables (eg, age, sex, employment status, education, income) was administered to all respondents. In addition, sample information was linked to interview location records to classify each respondent by major census region (Northeast, Midwest, South, and West), and by the Department of Agriculture's urban-rural continuum of counties (major metropolitan counties, other urbanized counties, and rural counties).
Interviewer Training and Field Quality Control
Professional lay interviewers from the Institute for Social Research at the University of Michigan administered the NCS-R. More than 300 interviewers participated in the study, each receiving 7 days of study-specific training and successfully completing 2 practice interviews before beginning production work. Interviews were administered using laptop computer–assisted software that included built-in skip logic, timing flags, and consistency checks. Regional supervisors recontacted a random 10% of respondents for quality control.
Five experienced clinical psychologists administered the clinical reappraisal SCID interviews. Each received 80 hours of training and successfully completed 2 practice interviews before beginning production work. Interviews were conducted by telephone and were tape recorded with the verbal permission of respondents. Interviewers wrote extensive notes to justify ratings. A clinical supervisor reviewed the notes and reviewed the tape recordings of the first 10 interviews for each interviewer plus other tape recordings as needed. The interviewer or supervisor recontacted the respondent to obtain additional information when there was ambiguity about ratings. Biweekly review meetings were used to prevent interviewer drift.
Statistical Analysis
Cross-tabulations were used to calculate prevalence, comorbidity, symptom severity, impairment, treatment, and treatment adequacy. The Kaplan-Meier method42 was used to generate age-at-onset curves. Logistic regression analysis43 was used to study demographic correlates of prevalence and treatment. The logistic regression coefficients were transformed to odds ratios (ORs) for ease of interpretation. Ninety-five percent confidence intervals (CIs) were estimated using the Taylor series linearization method implemented in the SUDAAN software package.44 Multivariate significance tests were calculated using Wald 2 tests based on coefficient variance-covariance matrices that were adjusted for design effects using the Taylor series method. Statistical significance was based on 2-sided design-based tests evaluated at the .05 level of significance.
RESULTS
Prevalence of MDD
The prevalence estimates for CIDI/DSM-IV MDD in the total NCS-R sample were 16.2% (95% CI, 15.1-17.3) for lifetime and 6.6% (95% CI, 5.9-7.3) for the 12 months before the interview; the ratio of 12-month to lifetime prevalence was approximately 40%. These prevalences were equivalent to national population projections of 32.6 to 35.1 million US adults with lifetime MDD and 13.1 to 14.2 million with 12-month MDD.
Age-At-Onset of MDD
Kaplan-Meier curves for age-at-onset of MDD were generated separately for 4 groups of birth cohorts (Figure 1) and defined by age at interview (18-29, 30-44, 45-59, or ≥60 years). The curves are significantly different from each other (23 = 290.1, P <.001 for all). Risk is fairly low until the early teens, when it begins to rise in roughly linear fashion with an increasingly steep slope in successively more recent cohorts.
|
|
|
|
Figure. Cumulative Lifetime Prevalence of CIDI/DSM-IV Major Depressive Disorder by Birth Cohort
23 = 290.1, P<.001 for all. Analysis used weighted data.
|
|
|
Sociodemographic Correlates
Either lifetime MDD or 12-month MDD among lifetime cases was meaningfully elevated (ie, statistically significant at the .05 level with ORs ≥1.5) among respondents in the age range of 18 years to 59 years for lifetime or 18 years to 44 years for 12-month, and for women (lifetime only), homemakers (12-month only), respondents who were classified as "other" in employment status (consisting mainly of those who were unemployed or disabled), the never married (12-month only), the previously married (lifetime only), those with less than 12 years of education (12-month only), and those living in or near poverty (http://aspe.hhs.gov/poverty/01poverty.htm) (12-month only). (Table 3) Other employment status, being previously married, and low income also were associated with meaningfully elevated severe MDD (defined by the QIDS-SR) among 12-month cases. The prevalence of lifetime MDD was meaningfully lower (ie, statistically significant at the .05 level with ORs ≤0.67) among people who were retired and Non-Hispanic blacks than among comparison cases, while 12-month MDD was less likely to be clinically severe in the Northeast and Midwest than other regions of the country. Major depressive disorder was largely unrelated to geography (region of the country or urbanicity). Despite the large number of meaningful associations, only a few were strong (ie, ORs >3.0 or <0.33).
|
|
|
|
Table 3. Bivariate Sociodemographic Correlates of 12-Month and Lifetime CIDI/DSM-IV for Major Depressive Disorder (MDD) in the Weighted Part 2 NCS-R Sample
|
|
|
Comorbidity
Nearly three fourths (72.1%) of respondents with lifetime MDD also met the criteria for at least 1 of the other CIDI/DSM-IV disorders assessed in the NCS-R, including 59.2% with anxiety disorder, 24.0% with substance use disorder, and 30.0% with impulse control disorder. (Table 4) Approximately two thirds (64.0%) of respondents with 12-month MDD met the criteria for at least 1 other 12-month disorder, with anxiety disorders (57.5%) again more common than either substance use (8.5%) or impulse control (16.6%) disorders (Table 4). Comparison of age-at-onset reports (Table 4) shows MDD to be temporally primary to all other comorbid disorders among 12.3% of respondents with lifetime MDD and 12.6% of those with 12-month MDD. For lifetime and 12-month MDD, temporally prior MDD was much more common in relation to substance use disorders (41.3% and 49.2%) than either anxiety (13.7% and 14.6%) or impulse control (16.9% and 20.8%) disorders.
|
|
|
|
Table 4. Comorbidity of CIDI/DSM-IV Major Depressive Disorders With Other NCS-R Disorders in the Weighted Part 2 NCS-R*
|
|
|
Role Impairment of 12-Month MDD
Nearly all (96.9%) respondents with 12-month MDD reported at least some role impairment associated with their depression in at least 1 of the 4 SDS role domains, with 87.4% describing this impairment as at least moderate, 59.3% as either severe or very severe, and 19.1% as very severe. (Table 5) Impairment was greatest in the social role domain (43.4% severe or very severe) and was least in the work role domain (28.1% severe or very severe).
|
|
|
|
Table 5. Severity of Role Impairment by the Sheehan Disability Scale Associated With 12-Month CIDI/DSM-IV Major Depressive Disorder in the Weighted Part 1 NCS-R Sample (n = 622)
|
|
|
Respondents with 12-month MDD reported a mean of 35.2 (95% CI, 26.8-43.6) days in the past year when they were totally unable to work or carry out their normal activities because of their depression. Overall SDS scores are significantly related (F4,617 = 17.1, P<.001) to days out of role (Table 5), from a high of 96.5 days among respondents who reported very severe role impairment to a low of zero among those who reported no role impairment.
Comparison of respondents with MDD vs those with no lifetime history of MDD on the WHO-DAS dimensions provides additional evidence of broad-based impairment associated with MDD (Table 6). Recent MDD (within 30 days of the interview) is associated with statistically significant impairments in all 6 WHO-DAS domains compared with respondents who never met criteria for MDD. These include impairments more than a full SD above the sample-wide mean in 30-day cognitive functioning and social functioning, more than 75% of an SD above the mean in days out of role and role functioning, more than 60% of an SD above the mean in mobility, and nearly 50% of an SD above the mean in self-care (all adjusted for age, sex, and race/ethnic differences between respondents with and without MDD). These impairments appear to be state dependent, as the mean levels of impairment among respondents who had an episode of MDD earlier in the year are less strongly and consistently elevated (4 of the 6 WHO-DAS scores significantly elevated, with effect sizes 20%-45% of an SD about the mean), while respondents with a history of MDD who were not depressed in the past year have no significant elevations on any of the WHO-DAS dimensions.
|
|
|
|
Table 6. Thirty-Day Standardized Comparisons of Functional Impairment by the WHO-DAS Among Respondents With vs Without CIDI/DSM-IV Major Depressive Disorder in the Weighted Part 2 NCS-R*
|
|
|
Clinical Severity of 12-Month MDD
More than 99% of respondents with 12-month CIDI/DSM-IV MDD are independently classified by the QIDS-SR as having been clinically depressed during the worst month of the year, with 10.4% mild, 38.6% moderate, 38.0% severe, and 12.9% very severe (Table 7). Mild through severe cases as measured by QIDS-SR have mean durations of 13.8 to 16.6 weeks, while very severe cases have a mean duration of 23.1 weeks (Table 7). Symptom severity is strongly related both to role impairment and to comorbidity.
|
|
|
|
Table 7. Distributions and Correlates of Symptom Severity by Quick Inventory of Depressive Symptomatology Self-Report of 12-Month CIDI/DSM-IV Major Depressive Disorder in the Weighted Part 1 NCS-R*
|
|
|
12-Month Treatment
An estimated 57.3% of respondents with 12-month MDD received some type of treatment in the 12 months before their interview (Table 8). The SMH sector was involved in the highest proportion of these cases (55.1% of treated cases) and the HS sector in the lowest proportion (16.0% of treated cases), with 90.0% of treated cases seen in the health care (HC) sectors (SMH, GM, or psychotropic medication use). Treatment met our criteria for being at least minimally adequate in 64.3% (95% CI, 55.4-73.1) of cases in SMH treatment, 41.3% (95% CI, 31.3-57.2) of cases in GM treatment, and 41.9% (95% CI, 35.9-47.9) in HC treatment (Table 8). Given that 51.6% (95% CI, 46.1-57.2) of cases received HC treatment for their depression, no more than 21.6% of all respondents with 12-month MDD (ie, 41.9% of the 51.6% in treatment) received adequate treatment in the year of the interview.
|
|
|
|
Table 8. Treatment in the Past 12 Months and Treatment Adequacy of 12-Month CIDI/DSM-IV Major Depressive Disorder by Symptom Severity Assessed by Quick Inventory of Depressive Symptomatology Self-Report in the Weighted Part 2 NCS-R
|
|
|
Because there was overlap in sectors of treatment, we also compared respondents who received SMH, but not GM, treatment (n = 99), among whom 56.2% (95% CI, 43.7-68.7) received adequate treatment, with those who received GM, but not SMH, treatment (n = 74), among whom a significantly lower 9.6% (95% CI, 6.0-15.5) received adequate treatment (z = 6.3, P<.001).
Symptom severity is significantly related to 12-month treatment in both the SMH sector (23 = 13.4, P = .004) and the GM sector (23 = 8.1, P = .04), but not in either the HS sector (23 = 0.2, P = .97) or the CAM sector (23 = 2.6, P = .46). Symptom severity is also significantly related to patients in the SMH sector receiving adequate treatment (23 = 7.9, P = .048). Even so, fewer than half the respondents with 12-month very severe MDD (39.1%) and fewer than one fourth of those with 12-month severe MDD (24.6%) received adequate 12-month HC treatment for MDD.
In addition to symptom severity, other clinical correlates of treatment and treatment adequacy include role impairment, duration, proportional days out of role during depressive episodes, and psychiatric comorbidity (Table 9). Sociodemographic correlates of treatment adequacy also were examined (results not shown, but available on request from R.C.K.) using the same measures and procedures as in Table 3. None of these measures was significantly related to adequate treatment after adjusting statistically for clinical variables.
|
|
|
|
Table 9. Bivariate Clinical Predictors of 12-Month Treatment and Treatment Adequacy Among Respondents With 12-Month CIDI/DSM-IV Major Depressive Disorder in the Weighted Part 1 NCS-R
|
|
|
COMMENT
The NCS-R MDD prevalence estimates are intermediate between the ECA and NCS estimates. Concordance between CIDI and clinical reappraisal diagnoses in the NCS-R is higher than in previous DIS and CIDI surveys.32, 45 In addition, the QIDS-SR confirms more than 99% of 12-month CIDI MDD cases. This improved accuracy is presumably because of CIDI modifications in the NCS-R. The lower CIDI prevalence estimates than those in the NCS are consistent with the fact that these modifications operated largely by reducing false-positive assessments.
The ratio of 12-month CIDI MDD prevalence to lifetime prevalence being approximately 40% is broadly consistent with ratios between one third and one half in previous epidemiologic surveys.46-47 These ratios are consistent with both retrospective reports in cross-sectional community surveys7, 11 and prospective assessments in a small number of community48-49 and clinical50 samples in suggesting that MDD is an episodically chronic recurrent disorder.51
The NCS-R age-at-onset results are consistent with previous surveys in finding that MDD has an early onset distribution.12, 46, 52 The strong MDD cohort effect in NCS-R also is consistent with previous surveys.13, 46, 53 Age-related differential recall, differential willingness to disclose, or other methodologic factors could play important parts in this pattern,54-55 although a genuine increase in the prevalence of MDD in recent cohorts might have occurred.56-57
The sociodemographic correlates of prevalence are for the most part consistent with those of previous epidemiologic studies,46, 58-66 as is the finding that MDD is comorbid with anxiety and substance use disorders.67-68 Although little epidemiologic evidence is available about comorbidity between depression and impulse control disorders among adults, significant comorbidity for MDD and impulse control disorder has been documented in clinical studies.69-70 Comorbid impulse control disorder is often thought to be more strongly related to bipolar than to unipolar depression.71 The NCS-R MDD impulse control disorder comorbidity could reflect broader factors or the existence of what has recently been called a "soft bipolar spectrum" in which comorbid impulse control disorder among patients with MDD represents a marker of bipolar susceptibility.72
The finding that comorbid anxiety disorders typically have an earlier age of onset than does MDD is consistent with previous epidemiologic research46 as well as with prospective family studies of at-risk children.73 The finding that the same is true for comorbid impulse control disorder has not, to our knowledge, been examined in previous epidemiologic studies of adults, although the evidence on this point is mixed in studies of children and adolescents.74
The results regarding MDD impairment are consistent with other evidence that MDD is a seriously impairing condition.75 The 35.1 mean days out of role because of MDD is striking in comparison with recent results from another national survey in which mean time out of role was less than 15 days for most chronic conditions.76
The QIDS-SR symptom severity results speak directly to the concern that prevalence estimates in community surveys might be upwardly biased due to the inclusion of clinically insignificant cases.29 This concern is clearly misplaced with respect to MDD, as close to 90% of 12-month CIDI cases are classified as moderate, severe, or very severe using standard HRSD symptom severity thresholds.
The 57.3% of 12-month MDD cases who received treatment in the past year, when multiplied by the estimated 12-month prevalence of MDD, represents 3.7% of the population. This is a meaningful increase over the 2.1% in the ECA in the early 1980s and the 2.7% in the NCS in 1990-1991.14, 16 The ratio of NCS-R to ECA percentages (3.7:2.1) represents a 37% increase in MDD treatment. This large increase is consistent with trend data from the National Medical Expenditures Survey for changes between 1987 and 1997.18
The NCS-R results are less positive with regard to treatment adequacy, implying a need for treatment quality improvement.77 This improvement will require both a redirection of patient help-seeking to sectors where guideline-concordant care can be provided and an increase in the implementation of evidence-based treatment recommendations by health care providers.40-41 The growing number of cost-effective depression disease management programs24, 26, 78 represent feasible opportunities for promoting quality improvement. However, implementation of established performance standard79 and report card80 monitoring systems also are needed for quality assurance.
AUTHOR INFORMATION
| |
Corresponding Author and Reprints: Ronald C. Kessler, PhD, Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115 (e-mail: NCS{at}hcp.med.harvard.edu).
Author Contributions: Study concept and design: Kessler, Koretz, Merikangas, Rush, Wang.
Acquisition of data: Kessler, Berglund, Jin, Merikangas, Walters.
Analysis and interpretation of data: Kessler, Berglund, Demler, Koretz, Walters, Wang.
Drafting of the manuscript: Kessler, Berglund, Jin, Merikangas, Wang.
Critical revision of the manuscript for important intellectual content: Kessler, Berglund, Demler, Koretz, Merikangas, Rush, Walters, Wang.
Statistical expertise: Kessler, Berglund, Demler, Walters.
Obtained funding: Kessler.
Administrative, technical, or material support: Kessler, Jin, Koretz, Merikangas, Rush.
Study supervision: Kessler, Walters.
Funding/Support: The National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (U01-MH60220) with supplemental support from the National Institute of Drug Abuse, the Substance Abuse and Mental Health Services Administration, and the Robert Wood Johnson Foundation (grant 044780).
Collaborating Investigators: Ronald C. Kessler (principal investigator, Harvard Medical School), Kathleen Merikangas (coprincipal investigator, NIMH), Doreen Koretz (coprincipal investigator, NIMH), William Eaton (Johns Hopkins University), Jane McLeod (Indiana University), Mark Olfson (Columbia University College of Physicians and Surgeons), Harold Pincus (University of Pittsburgh), Phillip Wang (Harvard Medical School), Kenneth Wells (University of California–Los Angeles and RAND), and Elaine Wethington (Cornell University).
Disclaimer: The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of any of the sponsoring organizations, agencies, or the US Government.
Additional Information: The instruments for NCS-R are posted at: http://www.hcp.med.harvard.edu/ncs/instruments.html.
Author Affiliations: Department of Health Care Policy, Harvard Medical School, Boston, Mass (Drs Kessler and Wang, Mss Demler and Walters, and Mr Jin); Institute for Social Research, University of Michigan, Ann Arbor (Ms Berglund); Division of Mental Disorders, Behavioral Research and AIDS (Dr Koretz), and Intramural Research Program (Dr Merikangas), National Institute of Mental Health, Rockville, Md; Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (Dr Rush); Brigham and Womens' Hospital, Harvard Medical School (Dr Wang).
REFERENCES
1. Comstock GW, Helsing KJ. Symptoms of depression in two communities. Psychol Med. 1976;6:551-563.
ISI
| PUBMED
2. Helgason T. Epidemiology of mental disorders in Iceland. Acta Psychiatr Scand. 1964;40:115-132.
PUBMED
3. Lin TY. A study of incidence of mental disorders in Chinese and other cultures. Psychiatry. 1953;16:315-335.
PUBMED
4. Robins LN, Helzer JE, Croughan JL, Ratcliff KS. National Institute of Mental Health Diagnostic Interview Schedule. Arch Gen Psychiatry. 1981;38:381-389.
FREE FULL TEXT
5. Robins LN, ed, Regier DA, ed. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Third Edition: DSM-III. 1st ed. Washington, DC: American Psychiatric Association; 1980.
7. Weissman MM, Livingston Bruce M, Leaf PJ, Florio LP, Holzer CI. Affective disorders. In: Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991:53-80.
8. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry. 1994;51:8-19.
FREE FULL TEXT
9. Robins LN, Wing J, Wittchen H-U, et al. The Composite International Diagnostic Interview. Arch Gen Psychiatry. 1988;45:1069-1077.
FREE FULL TEXT
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Third Edition—Revised): DSM-III-R. Washington, DC: American Psychiatric Association; 1987.
11. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population. Br J Psychiatry. 1996;168:17-30.
12. Christie KA, Burke JDJ, Regier DA, Rae DS, Boyd JH, Locke BZ. Epidemiologic evidence for early onset of mental disorders and higher risk of drug-abuse in young-adults. Am J Psychiatry. 1988;145:971-975.
FREE FULL TEXT
13. Kessler RC, Magee WJ. Childhood adversities and adult depression. Psychol Med. 1993;23:679-690.
ISI
| PUBMED
14. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 1990;264:2511-2518.
FREE FULL TEXT
15. Regier DA, Kaelber CT, Rae DS, et al. Limitations of diagnostic criteria and assessment instruments for mental disorders: implications for research and policy. Arch Gen Psychiatry. 1998;55:109-115.
FREE FULL TEXT
16. Kessler RC, Zhao S, Katz SJ, et al. Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey. Am J Psychiatry. 1999;156:115-123.
FREE FULL TEXT
17. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US Mental and Addictive Disorders Service System. Arch Gen Psychiatry. 1993;50:85-94.
FREE FULL TEXT
18. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. 2002;287:203-209.
FREE FULL TEXT
19. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333-340.
FREE FULL TEXT
20. Regier DA, Hirschfeld RMA, Goodwin FK, Burke JD, Lazar JB, Judd LL. The NIMH Depression, Awareness, Recognition and Treatment Program. Am J Psychiatry. 1988;145:1351-1357.
FREE FULL TEXT
21. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. JAMA. 1989;262:914-919.
FREE FULL TEXT
22. Kouzis AC, Eaton WW. Emotional disability days: prevalence and predictors. Am J Public Health. 1994;84:1304-1307.
FREE FULL TEXT
23. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002.
24. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. JAMA. 1995;273:1026-1031.
FREE FULL TEXT
25. Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of disseminating quality improvement programs for depression in managed primary care. JAMA. 2000;283:212-220.
FREE FULL TEXT
26. Schoenbaum M, Unutzer J, Sherbourne C, et al. Cost-effectiveness of practice-initiated quality improvement for depression. JAMA. 2001;286:1325-1330.
FREE FULL TEXT
27. Pincus HA, Hough L, Houtsinger JK, Rollman BL, Frank RG. Emerging models of depression care. Int J Methods Psychiatr Res. 2003;12:54-63.
FULL TEXT
|
ISI
| PUBMED
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
29. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States. Arch Gen Psychiatry. 2002;59:115-123.
FREE FULL TEXT
30. Kessler RC, Merikangas KR, Berglund P, Eaton WW, Koretz D, Walters EE. Should mild disorders be eliminated from DSM-V? In press.
31. Kessler RC, Walters EE. The National Comorbidity Survey. In: Tsaung MT, Tohen M, eds. Textbook in Psychiatric Epidemiology. 2nd ed. New York, NY: John Wiley & Sons; 2002:343-362.
32. Kessler RC, Wittchen H-U, Abelson JM, et al. Methodological studies of the Composite International Diagnostic Interview (CIDI) in the US National Comorbidity Survey. Int J Methods Psychiatr Res. 1998;7:33-55.
FULL TEXT
33. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). New York, NY: Biometrics Research, New York State Psychiatric Institute; 1997.
34. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27:93-105.
ISI
| PUBMED
35. Rehm J, Ustun TB, Saxena S, et al. On the development and psychometric testing of the WHO screening instrument to assess disablement in the general population. Int J Methods Psychiatr Res. 1999;8:110-123.
FULL TEXT
36. Rush AJ, Carmody T, Reimitz P-E. The Inventory of Depressive Symptomatology (IDS). Int J Methods Psychiatr Res. 2000;9:45-59.
FULL TEXT
37. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS). Psychol Med. 1996;26:477-486.
ISI
| PUBMED
38. Hamilton M. A rating scale for depression. J Neurol Neurosur Psychiatry. 1960;23.
39. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR). Biol Psychiatry. In press.
40. American Psychiatric Association. Practice Guideline for Treatment of Patients With Major Depressive Disorder, Second Ed. Washington, DC: American Psychiatric Association Press; 2000.
41. Agency for Health Care Policy and Research. Depression in Primary Care: Vol 2: Treatment of Major Depression. Rockville, MD: US Dept of Health and Human Services; 1993.
42. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
FULL TEXT
|
ISI
43. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley & Sons; 1989.
44. Research Triangle Institute. Sudaan Release 8.0.1, January 2002. Research Triangle Park, NC: Research Triangle Institute; 2002.
45. Wittchen H-U. Reliability and validity studies of the WHO Composite International Diagnostic Interview (CIDI). J Psychiatr Res. 1994;28:57-84.
FULL TEXT
|
ISI
| PUBMED
46. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes. Int J Methods Psychiatr Res. 2003;12:3-21.
FULL TEXT
|
ISI
| PUBMED
47. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996;276:293-299.
FREE FULL TEXT
48. Angst J, Merikangas K. The depressive spectrum: diagnostic classification and course. J Affect Disord. 1997;45:31-39.
FULL TEXT
|
ISI
| PUBMED
49. Murphy JM, Sobol AM, Neff RK, Olivier DC, Leighton AH. Stability of prevalence. Arch Gen Psychiatry. 1984;41:990-997.
FREE FULL TEXT
50. Keller MB. Chronic and recurrent affective disorders: incidence, course and influencing factors. In: Kemali D, Racagni G, eds. Chronic Treatments in Neuropsychiatry. New York, NY: Raven Press; 1985.
51. US Department of Health and Human Services. Mental Health: A Report of the Surgeon General. Rockville, Md: US Dept of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health; 1999.
52. Blazer DG, Kessler RC, McGonagle K, Swartz M. The prevalence and distribution of major depression in a national community sample. Am J Psychiatry. 1994;151:979-986.
FREE FULL TEXT
53. Cross-National Collaborative Group. The changing rate of major depression. JAMA. 1992;268:3098-3105.
FREE FULL TEXT
54. Giuffra LA, Risch N. Diminished recall and the cohort effect of major depression. Psychol Med. 1994;24:375-383.
ISI
| PUBMED
55. Simon GE, Von Korff M. Recall of psychiatric history in cross-sectional surveys. Epidemiol Rev. 1995;17:221-227.
FREE FULL TEXT
56. Kessler RC. Gender differences in major depression: epidemiologic findings. In: Frank E, ed. Gender and Its Effect on Psychopathology. Washington, DC: American Psychiatric Press Inc; 2000:61-84.
57. Kessler RC, McGonagle KA, Nelson CB, Hughes M, Swartz M, Blazer DG. Sex and depression in the National Comorbidity Survey II. J Affect Disord. 1994;30:15-26.
FULL TEXT
|
ISI
| PUBMED
58. Bland RC, Orn H, Newman SC. Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand Suppl. 1988;77(suppl 338):24-32.
59. Canino GJ, Bird HR, Shrout PE, et al. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry. 1987;44:727-735.
FREE FULL TEXT
60. Hwu HG, Yeh EK, Cheng LY. Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule. Acta Psychiatr Scand. 1989;79:136-147.
ISI
| PUBMED
61. Lee CK, Kwak YS, Yamamoto J, et al. Psychiatric epidemiology in Korea: part I. J Nerv Ment Dis. 1990;178:242-246.
ISI
| PUBMED
62. Lépine JP, Lellouch J, Lovell A, et al. Anxiety and depressive disorders in a French population. Psychiatr Psychobiol. 1989;4:267-274.
63. Wittchen H-U, Essau CA, von Zerssen D, Krieg CJ, Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich Follow-up Study. Eur Arch Psychiatry Clin Neurosci. 1992;241:247-258.
FULL TEXT
|
ISI
| PUBMED
64. Wells JE, Bushnell JA, Hornblow AR, Joyce PR, Oakley-Browne MA. Christchurch Psychiatric Epidemiology Study, part I. Aust N Z J Psychiatry. 1989;23:315-326.
ISI
| PUBMED
65. Bland RC, Newman SC, Orn H. Period prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand Suppl. 1988;77(suppl 338):33-42.
66. Weissman MM, Meyers JK. Affective disorders in a US urban community. Arch Gen Psychiatry. 1978;35:1304-1311.
FREE FULL TEXT
67. Merikangas KR, Angst J, Eaton WW, et al. Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse. Br J Psychiatry. 1996;168:58-67.
68. Kessler RC. The prevalence of psychiatric comorbidity. In: Wetzler S, Sanderson WC, eds. Treatment Strategies for Patients With Psychiatric Comorbidity. New York, NY: John Wiley & Sons; 1997.
69. Lejoyeux M, Arbaretaz M, McLoughlin M, Ades J. Impulse control disorders and depression. J Nerv Ment Dis. 2002;190:310-314.
FULL TEXT
|
ISI
| PUBMED
70. Zimmerman M, Chelminski I, McDermut W. Major depressive disorder and axis I diagnostic comorbidity. J Clin Psychiatry. 2002;63:187-193.
ISI
| PUBMED
71. McElroy SL, Pope HG, Keck PE Jr, Hudson JI, Phillips KA, Strakowski SM. Are impulse-control disorders related to bipolar disorder? Compr Psychiatry. 1996;37:229-240.
FULL TEXT
|
ISI
| PUBMED
72. Perugi G, Akiskal HS, Lattanzi L, et al. The high prevalence of "soft" bipolar (II) features in atypical depression. Compr Psychiatry. 1998;39:63-71.
FULL TEXT
|
ISI
| PUBMED
73. Warner V, Weeisman MM, Mufson L, Wickramaratne PJ. Grandparents, parents, and grandchildren at high risk for depression. J Am Acad Child Adolesc Psychiatry. 1999;38:289-296.
FULL TEXT
|
ISI
| PUBMED
74. Loeber R, Farrington DP, Stouthamer-Loeber M, Van Kammen WB. Antisocial Behavior and Mental Health Problems: Explanatory Factors in Childhood and Adolescence. Mahwah, NJ: Lawrence Earlbaum Associates; 1988.
75. Wang PS, Simon GE, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res. 2003;12:22-33.
FULL TEXT
|
ISI
| PUBMED
76. Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med. 2001;43:218-225.
FULL TEXT
|
ISI
| PUBMED
77. Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A. The cost utility of screening for depression in primary care. Ann Intern Med. 2001;134:345-360.
FREE FULL TEXT
78. Katon W, Robinson P, VonKorff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry. 1996;53:924-932.
FREE FULL TEXT
79. National Committee for Quality Assurance. HEDIS 3.0: Narrative: What's in It and Why It Matters. Washington, DC: National Committee for Quality Assurance; 1997.
80. Substance Abuse and Mental Health Services Administration. Consumer-Oriented Mental Health Report Card. Rockville, Md: Center for Mental Health Services, SAMSHA; 1996.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Treatment of Depression by Mental Health Specialists and Primary Care Physicians
Allen J. Dietrich, Thomas E. Oxman, and John W. Williams, Jr
JAMA. 2003;290(15):1991.
EXTRACT
| FULL TEXT
Treatment of Depression by Mental Health Specialists and Primary Care Physicians
Mark H. Ebell
JAMA. 2003;290(15):1991-1992.
EXTRACT
| FULL TEXT
Treatment of Depression by Mental Health Specialists and Primary Care Physicians
Harold Alan Pincus
JAMA. 2003;290(15):1992.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression
Gaynes et al.
Psychiatr. Serv. 2009;60:1439-1445.
ABSTRACT
| FULL TEXT
The STAR*D Trial: Revealing the Need for Better Treatments
Insel and Wang
Psychiatr. Serv. 2009;60:1466-1467.
ABSTRACT
| FULL TEXT
Population-Based Service Planning for Implementation of MBCT: Linking Epidemiologic Data to Practice
Patten and Meadows
Psychiatr. Serv. 2009;60:1540-1542.
ABSTRACT
| FULL TEXT
Depression in adults, including those with a chronic physical health problem: summary of NICE guidance
Pilling et al.
BMJ 2009;339:b4108-b4108.
FULL TEXT
Recent Advances in Pharmacotherapy
Kemp and Brown
Journal of Pharmacy Practice 2009;22:446-466.
ABSTRACT
Selective serotonin reuptake inhibitors and congenital malformations
Chambers
BMJ 2009;339:b3525-b3525.
FULL TEXT
Downward Social Mobility and Major Depressive Episodes Among Latino and Asian-American Immigrants to the United States
Nicklett and Burgard
Am J Epidemiol 2009;170:793-801.
ABSTRACT
| FULL TEXT
Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials
Nelson and Papakostas
Am. J. Psychiatry 2009;166:980-991.
ABSTRACT
| FULL TEXT
Major Depressive Disorder in Long-Term Cancer Survivors: Analysis of the National Comorbidity Survey Replication
Pirl et al.
JCO 2009;27:4130-4134.
ABSTRACT
| FULL TEXT
The Relation of Maternal Sensitivity to Children's Internalizing and Externalizing Problems Within the Context of Maternal Depressive Symptoms
Garai et al.
Behav Modif 2009;33:559-582.
ABSTRACT
National Patterns in Antidepressant Medication Treatment
Olfson and Marcus
Arch Gen Psychiatry 2009;66:848-856.
ABSTRACT
| FULL TEXT
Major Depression and Coronary Artery Disease in the Swedish Twin Registry: Phenotypic, Genetic, and Environmental Sources of Comorbidity
Kendler et al.
Arch Gen Psychiatry 2009;66:857-863.
ABSTRACT
| FULL TEXT
Mental Health Correlates of Intimate Partner Violence in Marital Relationships in a Nationally Representative Sample of Males and Females
Afifi et al.
J Interpers Violence 2009;24:1398-1417.
ABSTRACT
A clinical prediction rule for detecting major depressive disorder in primary care: the PREDICT-NL study
Zuithoff et al.
Fam Pract 2009;26:241-250.
ABSTRACT
| FULL TEXT
Preventive, Lifestyle, and Personal Health Behaviors Among Physicians
Bazargan et al.
Acad. Psychiatry 2009;33:289-295.
ABSTRACT
| FULL TEXT
Help Seeking and Perceived Need for Mental Health Care Among Individuals in Canada With Suicidal Behaviors
Pagura et al.
Psychiatr. Serv. 2009;60:943-949.
ABSTRACT
| FULL TEXT
Depression and Costs of Health Care
Welch et al.
Psychosomatics 2009;50:392-401.
ABSTRACT
| FULL TEXT
Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes
Wisner et al.
Focus 2009;7:374-384.
ABSTRACT
| FULL TEXT
Social inequality in the prevalence of depressive disorders
Andersen et al.
J. Epidemiol. Community Health 2009;63:575-581.
ABSTRACT
| FULL TEXT
Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
Hewett et al.
J Psychopharmacol 2009;23:531-538.
ABSTRACT
Perceived Work and Family Conflict Among African American Nurses in College
Gipson-Jones
J Transcult Nurs 2009;20:304-312.
ABSTRACT
Clinical effectiveness of online computerised cognitive-behavioural therapy without support for depression in primary care: randomised trial
de Graaf et al.
Br. J. Psychiatry 2009;195:73-80.
ABSTRACT
| FULL TEXT
Embodiment of Sadness and Depression--Gait Patterns Associated With Dysphoric Mood
Michalak et al.
Psychosom. Med. 2009;71:580-587.
ABSTRACT
| FULL TEXT
Trends in Antidepressant Utilization From 2001 to 2004
Harman et al.
Psychiatr. Serv. 2009;60:611-616.
ABSTRACT
| FULL TEXT
Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes
Wisner et al.
Am. J. Psychiatry 2009;166:557-566.
ABSTRACT
| FULL TEXT
Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report
Wisniewski et al.
Am. J. Psychiatry 2009;166:599-607.
ABSTRACT
| FULL TEXT
Depression and C-Reactive Protein: Population-Based Health 2000 Study
Elovainio et al.
Psychosom. Med. 2009;71:423-430.
ABSTRACT
| FULL TEXT
Cortical thinning in persons at increased familial risk for major depression
Peterson et al.
Proc. Natl. Acad. Sci. USA 2009;106:6273-6278.
ABSTRACT
| FULL TEXT
Depression and heart rate variability in patients with coronary heart disease
CARNEY and FREEDLAND
Cleveland Clinic Journal of Medicine 2009;76:S13-S17.
ABSTRACT
| FULL TEXT
Major Depression as a Risk Factor for High Blood Pressure: Epidemiologic Evidence From a National Longitudinal Study
Patten et al.
Psychosom. Med. 2009;71:273-279.
ABSTRACT
| FULL TEXT
Do depression or antidepressants increase cardiovascular mortality? The absence of proof might be more important than the proof of absence.
Narayan and Stein
J Am Coll Cardiol 2009;53:959-961.
FULL TEXT
Unmet Need for Treatment of Major Depression in the United States
Mojtabai
Psychiatr. Serv. 2009;60:297-305.
ABSTRACT
| FULL TEXT
Changing Perceptions of Depression: Ten-Year Trends From the General Social Survey
Blumner and Marcus
Psychiatr. Serv. 2009;60:306-312.
ABSTRACT
| FULL TEXT
A Randomized Controlled Trial of Culturally Relevant, Brief Interpersonal Psychotherapy for Perinatal Depression
Grote et al.
Psychiatr. Serv. 2009;60:313-321.
ABSTRACT
| FULL TEXT
Relationships Among Depression, Chronic Pain, Chronic Disabling Pain, and Medical Costs
Arnow et al.
Psychiatr. Serv. 2009;60:344-350.
ABSTRACT
| FULL TEXT
Increased gender-based violence among women internally displaced in Mississippi 2 years post-Hurricane Katrina.
Anastario et al.
dmphp 2009;3:18-26.
ABSTRACT
| FULL TEXT
Depression Among Alumni of Foster Care: Decreasing Rates Through Improvement of Experiences in Care
White et al.
Journal of Emotional and Behavioral Disorders 2009;17:38-48.
ABSTRACT
The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated
Marrie et al.
Mult Scler 2009;15:385-392.
ABSTRACT
Neurobiological mechanisms in major depressive disorder
aan het Rot et al.
CMAJ 2009;180:305-313.
FULL TEXT
Translating Scientific Opportunity Into Public Health Impact: A Strategic Plan for Research on Mental Illness
Insel
Arch Gen Psychiatry 2009;66:128-133.
ABSTRACT
| FULL TEXT
Improving outpatient care of depression by implementing practice guidelines: a controlled clinical trial
Bermejo et al.
Int J Qual Health Care 2009;21:29-36.
ABSTRACT
| FULL TEXT
Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment
Haussleiter et al.
Therapeutic Advances in Neurological Disorders 2009;2:13-29.
ABSTRACT
Usefulness of the Beck Depression Inventory as a screening method for depression among the general population of Finland
Nuevo et al.
Scand J Public Health 2009;37:28-34.
ABSTRACT
Depression and Anxiety in the United States: Findings From the 2006 Behavioral Risk Factor Surveillance System
Strine et al.
Psychiatr. Serv. 2008;59:1383-1390.
ABSTRACT
| FULL TEXT
Complicated Grief and its Relationship to Mental Health and Well-Being Among Bosnian Refugees After Resettlement in the United States: Implications for Practice, Policy, and Research
Craig et al.
Traumatology 2008;14:103-115.
ABSTRACT
Agomelatine Treatment of Major Depressive Disorder
Dolder et al.
The Annals of Pharmacotherapy 2008;42:1822-1831.
ABSTRACT
| FULL TEXT
Exercise in the Prevention and Treatment of Adolescent Depression: A Promising but Little Researched Intervention
Dunn and Weintraub
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2008;2:507-518.
ABSTRACT
The Burden of Mental Disorders
Eaton et al.
Epidemiol Rev 2008;30:1-14.
ABSTRACT
| FULL TEXT
Blues from the Neighborhood? Neighborhood Characteristics and Depression
Kim
Epidemiol Rev 2008;30:101-117.
ABSTRACT
| FULL TEXT
Psychoanalytic and psychodynamic therapies for depression: the evidence base
Taylor
Adv. Psychiatr. Treat. 2008;14:401-413.
ABSTRACT
| FULL TEXT
Serotonin Syndrome Risks When Combining SSRI/SNRI Drugs and Triptans: Is the FDA's Alert Warranted?
Wenzel et al.
The Annals of Pharmacotherapy 2008;42:1692-1696.
ABSTRACT
| FULL TEXT
Antidepressant Use in Black and White Populations in the United States
Gonzalez et al.
Psychiatr. Serv. 2008;59:1131-1138.
ABSTRACT
| FULL TEXT
Systematic Use of Patient-Rated Depression Severity Monitoring: Is It Helpful and Feasible in Clinical Psychiatry?
Duffy et al.
Psychiatr. Serv. 2008;59:1148-1154.
ABSTRACT
| FULL TEXT
Pharmacists' Role in Depression Care: A Survey of Attitudes, Current Practices, and Barriers
Scheerder et al.
Psychiatr. Serv. 2008;59:1155-1160.
ABSTRACT
| FULL TEXT
Adolescent Cannabis Problems and Young Adult Depression: Male-Female Stratified Propensity Score Analyses
Harder et al.
Am J Epidemiol 2008;168:592-601.
ABSTRACT
| FULL TEXT
Depression in Patients with Diabetes: Does It Impact Clinical Goals?
Rush et al.
J Am Board Fam Med 2008;21:392-397.
ABSTRACT
| FULL TEXT
Mental Health Conditions are Associated With Increased Health Care Utilization Among Urban Family Medicine Patients
Fogarty et al.
J Am Board Fam Med 2008;21:398-407.
ABSTRACT
| FULL TEXT
Parenting Specificity: An Examination of the Relation Between Three Parenting Behaviors and Child Problem Behaviors in the Context of a History of Caregiver Depression
McKee et al.
Behav Modif 2008;32:638-658.
ABSTRACT
Occult Depressive Symptoms in Adolescent Emergency Department Patients
Biros et al.
Arch Pediatr Adolesc Med 2008;162:769-773.
ABSTRACT
| FULL TEXT
Testing Language Effects in Psychiatric Epidemiology Surveys with Randomized Experiments: Results from the National Latino and Asian American Study
Shrout et al.
Am J Epidemiol 2008;168:345-352.
ABSTRACT
| FULL TEXT
Sildenafil Treatment of Women With Antidepressant-Associated Sexual Dysfunction: A Randomized Controlled Trial
Nurnberg et al.
JAMA 2008;300:395-404.
ABSTRACT
| FULL TEXT
Psychiatric Disorders in Pregnant and Postpartum Women in the United States
Vesga-Lopez et al.
Arch Gen Psychiatry 2008;65:805-815.
ABSTRACT
| FULL TEXT
Mental health care in the primary care setting: Family physicians' perspectives
Clatney et al.
cfp 2008;54:884-889.
ABSTRACT
| FULL TEXT
Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications
Vanoli et al.
J Psychopharmacol 2008;22:434-440.
ABSTRACT
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
Anderson et al.
J Psychopharmacol 2008;22:343-396.
ABSTRACT
Mediators of Depressive Symptoms in Children with Type 1 Diabetes and their Mothers
Jaser et al.
J Pediatr Psychol 2008;33:509-519.
ABSTRACT
| FULL TEXT
VGF, a New Player in Antidepressant Action?
Malberg and Monteggia
Sci Signal 2008;1:pe19-pe19.
ABSTRACT
| FULL TEXT
Depression After Diagnosis of Advanced Non-Small Cell Lung Cancer and Survival: A Pilot Study
Pirl et al.
Psychosomatics 2008;49:218-224.
ABSTRACT
| FULL TEXT
Population Attributable Fractions of Psychiatric Disorders and Suicide Ideation and Attempts Associated With Adverse Childhood Experiences
Afifi et al.
AJPH 2008;98:946-952.
ABSTRACT
| FULL TEXT
Depression in Patients With Heart Failure: Prevalence, Pathophysiological Mechanisms, and Treatment
Thomas et al.
Crit Care Nurse 2008;28:40-55.
FULL TEXT
Using Computerized Adaptive Testing to Reduce the Burden of Mental Health Assessment
Gibbons et al.
Psychiatr. Serv. 2008;59:361-368.
ABSTRACT
| FULL TEXT
Depression and Ischemic Heart Disease Mortality: Evidence From the EPIC-Norfolk United Kingdom Prospective Cohort Study
Surtees et al.
Am. J. Psychiatry 2008;165:515-523.
ABSTRACT
| FULL TEXT
Equity in Veterans' Mental Health Care: Veterans Affairs Medical Center Clinics Versus Community-Based Outpatient Clinics
Kirchner et al.
American Journal of Medical Quality 2008;23:128-135.
ABSTRACT
Trait Negative Affect: Toward an Integrated Model of Understanding Psychological Risk for Impairment in Cardiac Autonomic Function
Bleil et al.
Psychosom. Med. 2008;70:328-337.
ABSTRACT
| FULL TEXT
Prevalence of Mental Illness in Immigrant and Non-Immigrant U.S. Latino Groups
Alegria et al.
Am. J. Psychiatry 2008;165:359-369.
ABSTRACT
| FULL TEXT
Problem-Solving Therapy for Depression in Adults: A Systematic Review
Gellis and Kenaley
Research on Social Work Practice 2008;18:117-131.
ABSTRACT
Impact of comorbidity on headache-related disability
Saunders et al.
Neurology 2008;70:538-547.
ABSTRACT
| FULL TEXT
Major Depressive Disorder
Belmaker and Agam
NEJM 2008;358:55-68.
FULL TEXT
Adequacy of Antidepressant Treatment in Spanish Primary Care: A Naturalistic Six-Month Follow-Up Study
Pinto-Meza et al.
Psychiatr. Serv. 2008;59:78-83.
ABSTRACT
| FULL TEXT
Recent Findings in the Pathophysiology of Depression
Nemeroff
Focus 2008;6:3-14.
FULL TEXT
Strategies for the Prevention and Treatment of Suicidal Behavior
Clayton and Auster
Focus 2008;6:15-21.
ABSTRACT
| FULL TEXT
Immune System Contributions to the Pathophysiology of Depression
Miller and Raison
Focus 2008;6:36-45.
ABSTRACT
| FULL TEXT
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg et al.
Focus 2008;6:143-154.
ABSTRACT
| FULL TEXT
Depression, Posttraumatic Stress Disorder, and Mortality
Kinder et al.
Psychosom. Med. 2008;70:20-26.
ABSTRACT
| FULL TEXT
Does Stigma Keep Poor Young Immigrant and U.S.-Born Black and Latina Women From Seeking Mental Health Care?
Nadeem et al.
Psychiatr. Serv. 2007;58:1547-1554.
ABSTRACT
| FULL TEXT
Low Bone Mass in Premenopausal Women With Depression
Eskandari et al.
Arch Intern Med 2007;167:2329-2336.
ABSTRACT
| FULL TEXT
The Health Status of Patients of a Student-Run Free Medical Clinic in Inner-City Buffalo, NY
Cadzow et al.
J Am Board Fam Med 2007;20:572-580.
ABSTRACT
| FULL TEXT
A System-Based Approach to Depression Management in Primary Care Using the Patient Health Questionnaire-9
DeJesus et al.
Mayo Clin Proc. 2007;82:1395-1402.
ABSTRACT
| FULL TEXT
|
